Forte Biosciences (FBRX) Non-Current Deffered Revenue (2016 - 2019)
Forte Biosciences (FBRX) posted quarterly Non-Current Deffered Revenue of $2.3 million for Q1 2019, up 8414.81% year-over-year from $27000.0 in Q1 2018, and up 4.45% quarter-over-quarter from $2.2 million in Q4 2018.
Forte Biosciences (FBRX) Non-Current Deffered Revenue (2016 - 2019) Analysis & Trends
Forte Biosciences (FBRX) has reported Non-Current Deffered Revenue for 4 consecutive years, with $2.3 million the latest figure, recorded in Q1 2019.
- In Q1 2019, Non-Current Deffered Revenue rose 8414.81% year-over-year to $2.3 million; the TTM figure through Mar 2019 stood at $2.3 million (up 8414.81% YoY), while the FY2018 annual figure was $2.2 million, up 6013.89% from the prior year.
- Non-Current Deffered Revenue climbed to $2.3 million in Q1 2019 per FBRX's latest filing, from $2.2 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $2.3 million in Q1 2019 and bottomed at $27000.0 in Q1 2018.
- Historically, Non-Current Deffered Revenue has averaged $836100.0 across 4 years, with a median of $64500.0 in 2016.
- Annual changes were most pronounced in 2018 — Non-Current Deffered Revenue sank 55.74% — and 2019, when it surged 8414.81%.
- Forte Biosciences' Non-Current Deffered Revenue stood at $68000.0 in 2016, then tumbled by 47.06% to $36000.0 in 2017, then soared by 6013.89% to $2.2 million in 2018, then advanced by 4.45% to $2.3 million in 2019.
- Business Quant data shows FBRX's Non-Current Deffered Revenue at $2.3 million in Q1 2019, $2.2 million in Q4 2018, and $2.0 million in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 2.30 Mn |
| Dec 31, 2018 | 2.20 Mn |
| Sep 30, 2018 | 2.03 Mn |
| Jun 30, 2018 | 1.55 Mn |
| Mar 31, 2018 | 27,000.00 |
| Dec 31, 2017 | 36,000.00 |
| Sep 30, 2017 | 41,000.00 |
| Jun 30, 2017 | 51,000.00 |
| Mar 31, 2017 | 61,000.00 |
| Dec 31, 2016 | 68,000.00 |